Hematocrit On TRT After A Renal Artery Aneurysm
Timeline
Timestamp
Topic
00:00
A 44-year-old man on testosterone enanthate asks what hemoglobin and hematocrit levels are advisable after a renal artery aneurysm caused a blood clot, renal infarction, and partial loss of kidney function.
02:15
Dr. O’Connor explains how a clot associated with the renal artery aneurysm reduced blood flow to the kidney, produced an infarction, and left part of the kidney with diminished function.
03:03
Red blood cell production is reviewed through the interaction of the kidneys, erythropoietin, liver, iron metabolism, bone marrow, and androgens, including testosterone-induced erythrocytosis.
06:45
Dr. O’Connor raises fibromuscular dysplasia as a possible underlying cause of the renal artery aneurysm and discusses why additional vascular screening may be important if that diagnosis is confirmed.
20:30
The discussion returns directly to hemoglobin and hematocrit, with Dr. O’Connor explaining why there is no universal target and why clotting history, blood pressure, medications, iron studies, and other individual risks matter.
25:03
Dr. O’Connor warns against repeated phlebotomy simply to force hemoglobin or hematocrit lower because frequent blood removal can stimulate replacement red blood cell production while progressively depleting iron stores.
Video Summary
A 44-year-old man on testosterone asks how safe hematocrit levels change after a renal artery aneurysm. Dr. O’Connor explains how testosterone and other androgens can increase red blood cell production through erythropoietin and why hematocrit has to be interpreted alongside kidney function, iron status, blood pressure, sleep apnea, genetics, and other clotting risks.
The discussion expands beyond hematocrit because Dr. O’Connor believes the renal artery aneurysm deserves further investigation for an underlying vascular condition such as fibromuscular dysplasia. He discusses protecting remaining kidney function, screening for other aneurysms when appropriate, checking estimated GFR and other kidney markers, looking for protein in the urine, and closely following the ABCDs™.
Dr. O’Connor ultimately explains that there is no single ideal hemoglobin or hematocrit number for every man on testosterone, particularly when other vascular or clotting risks are present. He discusses keeping hematocrit well below 54 while individualizing decisions based on the complete clinical picture and strongly cautions against repeated phlebotomy simply to force hemoglobin or hematocrit to an unnecessarily low number because iron depletion can result.
Drug Callouts
Drug
Description
Testosterone Enanthate
The member is using 65 mg of testosterone enanthate per week divided into two doses. Dr. O’Connor explains that testosterone and other androgens can stimulate erythropoietin and red blood cell production, making hemoglobin and hematocrit important monitoring considerations in men on TRT.
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Dr. O’Connor specifically cautions the member about NSAIDs while discussing preservation of remaining kidney function. Because this man has already sustained renal injury, avoiding unnecessary kidney stress is presented as an important part of his long-term care while using testosterone.
Repatha (Evolocumab)
Repatha is discussed as a PCSK9-targeting cholesterol medication while Dr. O’Connor reviews modern approaches to reducing cardiovascular risk. The discussion occurs within his broader ABCDs™ framework for men using testosterone who need careful long-term cardiometabolic monitoring.
Farxiga (Dapagliflozin)
Farxiga is mentioned as a sodium-glucose cotransporter medication that may become relevant in certain patients with kidney concerns. Dr. O’Connor does not recommend it specifically for this member and states that substantially more medical information would be needed before determining whether such therapy is appropriate.
Jardiance (Empagliflozin)
Jardiance is discussed alongside Farxiga as another sodium-glucose cotransporter medication that may have a role in selected patients with kidney or cardiometabolic concerns. Dr. O’Connor makes clear that the member’s available history is insufficient to determine whether he would benefit from it.
Condition Callouts
Condition
Description
Renal Artery Aneurysm
The member previously experienced a small renal artery aneurysm that developed a clot and contributed to loss of kidney tissue. In a man using testosterone, this vascular history makes blood pressure, hematocrit, clotting risk, kidney function, and overall cardiovascular monitoring especially important.
Renal Infarction
A clot associated with the renal artery aneurysm reduced blood flow and caused a renal infarction, leaving approximately one-third of that kidney’s function impaired according to the member. Dr. O’Connor emphasizes protecting remaining renal function while continuing testosterone and avoiding additional cardiovascular or kidney stressors.
Androgen-Induced Erythrocytosis
Testosterone and other androgens can increase erythropoietin signaling and red blood cell production, raising hemoglobin and hematocrit in some men. Dr. O’Connor emphasizes that erythrocytosis should be interpreted together with iron studies, sleep apnea, smoking, genetics, blood pressure, and thrombotic risk rather than from one isolated number.
Fibromuscular Dysplasia
Dr. O’Connor raises fibromuscular dysplasia as a possible explanation for the member’s renal artery aneurysm but does not state that the diagnosis is confirmed. If present in a man using testosterone, the underlying vascular disease would make careful blood pressure and broader vascular surveillance particularly important.
Thrombosis
A blood clot was involved in the member’s prior renal event, and Dr. O’Connor repeatedly asks about additional clotting history and hypercoagulable conditions. This history matters when evaluating testosterone-related increases in hemoglobin and hematocrit because overall thrombotic risk depends on far more than the hematocrit value alone.
Hypertension
The member reports that his current blood pressure is optimal, but Dr. O’Connor repeatedly identifies hypertension as a major threat to kidney and cardiovascular health. Maintaining excellent blood pressure control is especially important for men on testosterone who already have renal or vascular disease.
Key Takeaways
- There is no single ideal hemoglobin or hematocrit target for every man on testosterone because vascular history, clotting risk, kidney function, iron status, sleep apnea, genetics, and other factors all influence the decision.
- Testosterone can increase erythropoietin and red blood cell production, making CBC and iron studies important parts of ongoing monitoring for androgen-induced erythrocytosis.
- A previous renal artery aneurysm and renal infarction make preservation of kidney function, blood pressure control, and broader vascular evaluation especially important while continuing TRT.
- Dr. O’Connor raises fibromuscular dysplasia as a possible cause of the renal artery aneurysm and recommends discussing that possibility and appropriate vascular screening with the member’s physicians.
- Hematocrit around 50 to 52 may not automatically require intervention, while Dr. O’Connor emphasizes keeping it well below 54 and individualizing decisions based on the complete risk profile.
- Repeated phlebotomy solely to force hemoglobin or hematocrit lower can deplete iron stores and should not be used automatically without considering the broader clinical picture.